patient that received Twinrix doses outside of the recommended timeframe (they had late doses), so they were administered another dose in September when they were seen in clinic; received 3rd dose on 09th Aug2018 and 4th dose on 3Dec2018; received second dose on 20Nov2017 and third sose on 09Aug2018; received first dose on 10Aug2015 and second dose on 20Nov2017; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 44-year-old female patient who received HAB (Twinrix) (batch number 797F9, expiry date 30-DEC-2025) for prophylaxis.   Co-suspect products included HAB (Twinrix) for prophylaxis, HAB (Twinrix) for prophylaxis and HAB (Twinrix) for prophylaxis.   Previously administered products included Twinrix (received 1st dose on 10th August 2015).   On 20-SEP-2023, the patient received the 5th dose of Twinrix. On 03-DEC-2018, the patient received the 4th dose of Twinrix. On 09-AUG-2018, the patient received the 3rd dose of Twinrix. On 20-NOV-2017, the patient received the 2nd dose of Twinrix. On 20-NOV-2017, not applicable after receiving Twinrix, Twinrix and Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: received first dose on 10Aug2015 and second dose on 20Nov2017). On 09-AUG-2018, the patient experienced drug dose administration interval too long (Verbatim: received second dose on 20Nov2017 and third sose on 09Aug2018). On 03-DEC-2018, the patient experienced extra dose administered (Verbatim: received 3rd dose on 09th Aug2018 and 4th dose on 3Dec2018). On 20-SEP-2023, the patient experienced extra dose administered (Verbatim: patient that received Twinrix doses outside of the recommended timeframe (they had late doses), so they were administered another dose in September when they were seen in clinic).The outcome of the drug dose administration interval too long, drug dose administration interval too long, extra dose administered and extra dose administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date:25-SEP-2023 The reporter was medical assistant. The reporter reported that office had patient that received Twinrix doses outside of the recommended timeframe (they had late doses), so they were administered another dose in September when they were seen in clinic. The doses prior to the 2023 dose were given at another location. The patient received 2nd dose of Twinrix later than the recommended schedule, which led to lengthening of vaccination schedule. The patient received 3rd dose of Twinrix later than the recommended schedule, which led to lengthening of vaccination schedule. The patient received 4th dose of Twinrix on 3rd December 2018, which led to extra dose administered. The patient received 5th dose of Twinrix on 20th September 2023 , which led to extra dose administered. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up. The case had been linked to US2023131773, reported by the same reporter, for a different patient.; Sender's Comments:  US-GSK-US2023131773:1st report